The anticipated size of the prophylactic HIV drugs market in 2022 was USD 31,278.5 million and is estimated to be USD 32,516.1 million in 2023.
Growth in the market is mainly due to an increase in research and development through investment in HIV clinical trials of pharmaceutical and biotechnology companies, increasing drug approvals for HIV, and a rise in the incidence of HIV in the population. According to Future Market Insights estimation, the market is predicted to expand at a CAGR of 4.1% between 2023 and 2033, totaling around USD 48,822.4 million by 2033.
The global prophylactic HIV drugs market size reached a valuation of around USD 30 billion in 2021. Due to the rising prevalence of HIV infection worldwide and growing awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs registered a 4% CAGR between 2022 and 2032, totaling over USD 40 billion in 2028.
Human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide affecting millions of people. The virus targets the immune system of infected patients and makes them vulnerable to many infections and cancers.
The condition can be managed through increasing access to effective prevention, diagnosis, treatment, and care although there is no permanent cure available for HIV infection. The rising focus on preventing the acquisition of HIV is one of the key factors pushing the demand for prophylactic HIV drugs.
Prophylactic HIV drugs are advanced therapeutics used to prevent getting HIV infection in certain circumstances as they have been especially effective in preventing the acquisition of HIV from sex and injection drug use.
Amid the rising prevalence of HIV, people across the world are showing a keen inclination toward consuming pre-exposure prophylaxis (PrEP) due to its better effectiveness. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex and injection drug use by around 99% and 74% respectively.
Prophylactic HIV drugs such as antiretroviral (ARV) are gaining immense popularity due to their ability to prevent and control HIV infection. Additionally, growing awareness among people regarding HIV and the benefits of prophylactic HIV drugs might continue to boost the sales of prophylactic HIV drugs during the forecast period.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | USD 31,278.5 million |
| Projected Forecast Value (2023) | USD 32,516.1 million |
| Projected Forecast Value (2033) | USD 48,822.4 million |
| Growth rate | 4.1% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global prophylactic drugs market expanded at a CAGR of 3.5% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 4.1% between 2023 and 2033.
Future growth of the market is estimated to boost by initiating various potential pipeline candidates like fostemsavir and PRO 140 by the drivers of generic versions of various branded drugs such as tenofovir disoproxil fumarate tablets.
Rise in HIV Cases Worldwide
The notable surge in HIV cases worldwide, continuous novel drug launches and approvals, and the increasing need for preventing and controlling HIV are some of the major factors stimulating the growth of the prophylactic HIV drugs market.
Prophylactic HIV drugs have become highly sought-after therapeutics for preventing the acquisition of HIV infection among people who are at high risk. Consumption of these drugs significantly reduces the chances of HIV infection. They are mostly recommended during sex and injection drug use where there is a high chance of HIV transmission.
The growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of the prophylactic HIV drugs market and the trend is likely to continue during the forecast period.
The increasing prevalence of HIV and its high mortality rate are pushing the demand for therapeutics like prophylactic HIV drugs. According to the World Health Organization (WHO), there were around 1.5 million newly infected cases of HIV and over 680000 deaths in 2020. This is prompting people to use prophylactic HIV drugs.
Increasing government initiatives and investments in spreading awareness among people about HIV, its symptoms, precautions, and treatment are expected to further expand the prophylactic HIV drug market size during the forecast period.
Principal Consultant
Side Effects Associated with Prophylactic HIV Drugs
Certain obstacles are challenging the growth of the prophylactic HIV drugs market despite its optimistic stance. Some of these obstacles include side effects associated with prophylactic HIV drugs, strict government approval for these drugs, and low awareness levels about these therapeutics across low emerging economies.
It has been observed that prophylactic HIV drugs often lead to side effects such as headache, depression, nausea, vomiting, abdominal pain, etc. Many people refrain from consuming these therapeutics. This in turn is limiting the growth of the prophylactic HIV drugs market.
Growth in North America Prophylactic HIV drugs market
According to FMI analysis, North America is likely to retain its dominant position in the global prophylactic HIV drugs market with a value share of 41.7%, accounting for a significant market share.
Moreover, growth in North America's prophylactic HIV drugs market is underpinned by the presence of a high level of awareness among people, the surge in HIV infection cases, the availability of advanced healthcare facilities, and the growing adoption of new therapeutics.
Demand for prophylactic HIV drugs is especially rising across countries like the United States and Mexico due to a surge in HIV cases. The rapid surge in cases of HIV infection in the United States holds a value share of 36.9% resulting in the rising incidences of unprotected sex and the use of unsterile injections.
Moreover, there were around 34800 new HIV infection cases reported in the USA. The rise in HIV infection cases is playing a key role in pushing the growth of the prophylactic HIV drugs market.
The Rising Prevalence of HIV Infection and Increasing Adoption of Novel Therapeutics
Amid the rising prevalence of HIV infection and increasing adoption of novel therapeutics, Europe's prophylactic HIV drugs market is likely to expand at a CAGR of 28% with a considerable pace during the forecast period.
Sharp rise in cases of HIV in countries of Europe like the United Kingdom expanding at a CAGR of 5.0%. As per the European Centre for Disease Prevention and Control, over 2.2 million people have been diagnosed and reported with HIV in the Europe Region according to WHO during the last three decades.
This in turn is fostering the growth of the prophylactic HIV drugs market in the region. Further, the presence of leading manufacturers such as ViiV Health is positively impacting the growth of the prophylactic HIV drugs market across Europe.
Introduction of Public Health Intervention for Minimization of HIV Transmission
Pre-exposure prophylaxis (PrEP) in China, is a newly introduced public health intervention for minimizing HIV transmission, where the coverage has remained limited expanding at a CAGR of 5%. Best delivery models and strategies for broadening access to vulnerable communities are not fully known.
Reviews have identified that PrEP programs reporting in India expanding at a CAGR of 4.1% were differentiated by delivery models that are accompanied by a healthcare accessibility framework.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) are Considered to have a Dominant Position in the Market
NRTIs are likely to hold a dominant position with a value share of 53.90%as it is mainly helpful if a person is pregnant or has other health conditions other than HIV.
NRTI mainly works by preventing the virus from further multiplying in the body. For example - HIV mainly, NRTIs work by blocking the reverse transcriptase, the enzyme that HIV needs to replicate itself.
Hospital Pharmacies are Preferred the Most in the Market
Hospital Pharmacies significantly hold a value share of 56.50% as people suffering from such a disease are likely to get cured in hospital pharmacies provided with proper treatment facilities.
Some of the prominent players operating in the global market are-
Notable Developments of the Key Players in the Market
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 4.1% from 2023 to 2033 |
| Market value in 2023 | USD 32,516.1 million |
| Market value in 2033 | USD 48,822.4 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD million for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
By Drug, By Distribution Channel, By Region |
| Regions Covered |
North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Key Countries Profiled | TheUnited States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled |
Gilead Sciences, Inc; Merck Sharp & Dohme Corp.; Merck & Co. Inc.; Mylan NV; Cipla Inc.; Genentech Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Health Care Systems Inc; Pfizer Inc.; GalaxoSmithKline PLC |
| Customization Scope | Available on Request |
The prophylactic HIV drugs market is set to attain a value of USD 32,516.1 million in 2023.
The prophylactic HIV drugs market is estimated to surpass USD 48,822.4 million by 2033.
The prophylactic HIV drugs market is projected to experience a CAGR of 4.1% through 2033.
North America's prophylactic HIV drugs market holds substantial revenue prospects, capturing a 41.7% value share.
With a commanding value share of 53.90%, the NRTI segment secures the top position in the prophylactic HIV drugs market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) 5.2. Integrase Inhibitor 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distributional Channel 6.1. Hospital Pharmacies 6.2. Retail Pharmacies 6.3. Mail Order Pharmacies 6.4. Drug Stores 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Gilead Sciences, Inc 17.2. Merck Sharp & Dohme Corp. 17.3. Merck & Co. Inc. 17.4. Mylan NV 17.5. Cipla Inc. 17.6. Genentech Inc. 17.7. Bristol-Myers Squibb Company 17.8. Johnson & Johnson Health Care Systems Inc 17.9. Pfizer Inc. 17.10. GlaxoSmithKline PLC 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Prophylactic HIV Drugs Market
